BEXIMCO PHARMA.GDR REGS 1 Asset Resilience Ratio
BEXIMCO PHARMA.GDR REGS 1 asset resilience ratio. BEXIMCO PHARMA.GDR REGS 1 (R2WA) has an Asset Resilience Ratio of 0.95% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See R2WA defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of BEXIMCO PHARMA.GDR REGS 1 (2024–2024)
Asset resilience ratio of BEXIMCO PHARMA.GDR REGS 1 from 2024 to 2024. This chart shows how BEXIMCO PHARMA.GDR REGS 1's Asset Resilience Ratio has changed over time. Read BEXIMCO PHARMA.GDR REGS 1 total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down BEXIMCO PHARMA.GDR REGS 1's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see BEXIMCO PHARMA.GDR REGS 1 total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €700.00 Million | 0.95% |
| Total Liquid Assets | €700.00 Million | 0.95% |
Asset Resilience Insights
- Limited Liquidity: BEXIMCO PHARMA.GDR REGS 1 maintains only 0.95% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
BEXIMCO PHARMA.GDR REGS 1 Industry Peers by Asset Resilience Ratio
Compare BEXIMCO PHARMA.GDR REGS 1's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
BEXIMCO PHARMA.GDR REGS 1 Asset Resilience Ratio by Year (2024–2024)
BEXIMCO PHARMA.GDR REGS 1 asset resilience ratio by year from 2024 to 2024. The table below shows the annual Asset Resilience Ratio data for BEXIMCO PHARMA.GDR REGS 1.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-06-30 | 0.29% | €200.00 Million ≈ $233.82 Million |
€69.34 Billion ≈ $81.07 Billion |
-- |
About BEXIMCO PHARMA.GDR REGS 1
Beximco Pharmaceuticals PLC. manufactures and markets generic pharmaceutical formulations and active pharmaceutical ingredients in Bangladesh. The company provides allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskelet… Read more